Therapy Detail

Therapy Name PQR309
Therapy Description

PQR309 (bimiralisib) is a dual pan-PI3K and mTORC1/2 inhibitor, which blocks PI3K/mTOR signaling, potentially resulting in inhibition of tumor growth (PMID: 29066507).

Filtering

  • Case insensitive filtering will display rows where any text in any cell matches the filter term
  • Simple literal full or partial string matches
  • Separate multiple filter terms with a spaces, order doesn't matter (a b c and c b a are equivalent )
  • Filtering will only apply to rows that are already loaded on the page, filtering has no impact on query parameters
  • Use quotes to match a longer phrase which contains spaces "mtor c1483f"

Sorting

  • Generally, the default sort order for tables is set to be first column ascending, however, specific tables may set a different default sort order.
  • Click on any column header arrows to sort by that column
  • Hold down the Shift key and click multiple columns to sort by more than one column, be sure to set ascending or descending order for a given column, before moving on to the next column.

Drug Name Trade Name Synonyms Drug Classes Drug Description
PQR309 PQR 309|bimiralisib mTOR Inhibitor 48 PI3K Inhibitor (Pan) 34 PQR309 (bimiralisib) is a dual pan-PI3K and mTORC1/2 inhibitor, which blocks PI3K/mTOR signaling, potentially resulting in inhibition of tumor growth (PMID: 29066507).
Molecular Profile Indication/Tumor Type Response Type Therapy Name Approval Status Evidence Type Efficacy Evidence References
Unknown unknown lymphoma not applicable PQR309 Preclinical - Cell culture Actionable In a preclinical study, PQR309 inhibited proliferation of lymphoma cells in culture, which was found to be due to the induction cell cycle arrest (PMID: 29066507). 29066507
Unknown unknown Advanced Solid Tumor not applicable PQR309 Phase I Actionable In a Phase I trial, PQR309 demonstrated safety and preliminary efficacy in patients with advanced solid tumors (J Clin Oncol 34, 2016 (suppl; abstr 2560)). detail...
Clinical Trial Phase Therapies Title Recruitment Status
NCT02249429 Phase Ib/II PQR309 Open-Label, Non Randomized Phase 2 Study With Safety Run-In Completed
NCT02669511 Phase II PQR309 PQR309 in Patients With Relapsed or Refractory Primary Central Nervous System Lymphoma Completed
NCT03740100 Phase II PQR309 Single-arm Study With Bimiralisib in Patients With HNSCC Harboring NOTCH1 Loss of Function Mutations Recruiting
NCT02483858 Phase I PQR309 Study of Oral PQR309 in Patients With Advanced Solid Tumors Active, not recruiting